Genuine Questions of C2010-659 exam - retain and pass exam | braindumps | ROMULUS

Download Pass4sure C2010-659 practice questions - VCE - examcollection - braindumps and exam prep They are added to our study guide for C2010-659 test prep - braindumps - ROMULUS

Pass4sure C2010-659 dumps | Killexams.com C2010-659 actual questions | http://tractaricurteadearges.ro/

C2010-659 Fundamentals of Applying SmartCloud Control Desk V1

Study guide Prepared by Killexams.com IBM Dumps Experts

Exam Questions Updated On :


Killexams.com C2010-659 Dumps and actual Questions

100% actual Questions - Exam Pass Guarantee with tall Marks - Just Memorize the Answers



C2010-659 exam Dumps Source : Fundamentals of Applying SmartCloud Control Desk V1

Test Code : C2010-659
Test name : Fundamentals of Applying SmartCloud Control Desk V1
Vendor name : IBM
: 103 actual Questions

the way to prepare for C2010-659 examination in shortest time?
in no way ever notion of passing the C2010-659 exam answering entire questions effectively. Hats off to you killexams. I wouldnt luxuriate in achieved this fulfillment with out the inspirit of your query and answer. It helped me draw nigh the principles and that i should solution even the unknown questions. it is the actual custom designed material which met my necessity for the duration of coaching. determined 90 percent questions commonplace to the guide and responded them quickly to deliver time for the unknown questions and it labored. thanks killexams.


am i able to find out finger data contemporaneous C2010-659 licensed?
Yes, very useful and I was able to score 82% in the C2010-659 exam with 5 days preparation. Especially the facility of downloading as PDF files in your package gave me a valid scope for effectual practice coupled with online tests - no limited attempts restriction. Answers given to each question by you is 100% accurate. Thanks a lot.


No cheaper supply than these C2010-659 dumps to be had but.
I handed the C2010-659 exam nowadays and scored a hundred%! Never view I should achieve it, but killexams.com grew to emerge as out to be a gem in exam training. I had a grotesque sentiment about it as it regarded to cowl entire topics, and there were masses of questions provided. Yet, I didnt hope to behold entire the equal questions within the actual exam. Very quality marvel, and that i quite recommend the employ of Killexams.


want up to date mind dumps for C2010-659 examination? here it's miles.
I am ranked very tall among my class mates on the list of outstanding students but it only happened after I registered on this killexams.com for some exam help. It was the tall ranking studying program on this killexams.com that helped me in joining the tall ranks along with other brilliant students of my class. The resources on this killexams.com are commendable because they are precise and extremely useful for preparation through C2010-659 pdf, C2010-659 dumps and C2010-659 books. I am providential to write these words of appreciation because this killexams.com deserves it. Thank you.


WTF! questions were exactly the selfsame in exam that I prepared!
I just bought this C2010-659 braindump, as quickly as I heard that killexams.com has the updates. Its authentic, they luxuriate in got covered entire unusual regions, and the exam looks very sparkling. Given the latest update, their rotate round time and aid is superb.


I got Awesome Questions and Answers for my C2010-659 exam.
Well, I did it and i cannot withhold in brain it. I must in no way luxuriate in passed the C2010-659 with out your help. My marks turned into so tall i was amazed at my tolerable performance. Its simply because of you. Thank you very lots!!!


Do a quick and smart pass, attach together those C2010-659 Questions and answers.
If you want perquisite C2010-659 education on the way it works and what are the tests and entire then dont blow a while and pick killexams.com as its miles an ultimate source of help. I likewise wanted C2010-659 training and I even opted for this extremely valid exam simulator and were given myself the best education ever. It guided me with every aspect of C2010-659 exam and provided the noteworthy questions and solutions I even luxuriate in ever seen. The observe guides likewise were of very a valid deal help.


What hold a notice at manual achieve I necessity to prepare to limpid C2010-659 examination?
Passing the C2010-659 was long due as I was extremely assiduous with my office assignments. But, when I institute the questions & answers by the killexams.com, it really inspired me to hold on the test. Its been really supportive and helped limpid entire my doubts on C2010-659 topic. I felt very joyful to pass the exam with a huge 97% marks. noteworthy achievement indeed. And entire credit goes to you killexams.com for this wonderful support.


Extract contemporaneous entire C2010-659 path contents in layout.
My brother saden me telling me that I wasnt going to vanish through the C2010-659 exam. I be watchful after I notice outdoor the window, such a lot of one of a kindhearted humans necessity to be seen and heard from and they simply want the attention people however i can disclose you that they students can find this attention while they pass their C2010-659 test and i will inform you how I cleared my C2010-659 test it turned into simplest when I were given my test questions from killexams.com which gave me the hope in my eyes collectively for entire time.


Did you tried these C2010-659 actual query monetary institution and study guide.
I desired to drop you a line to thanks on your test materials. This is the primary time I luxuriate in used your cram. I just took the C2010-659 today and handed with an eighty percent score. I must admit that I changed into skeptical in the climb but me passing my certification exam without a doubt proves it. Thanks a lot! Thomas from Calgary, Canada


IBM Fundamentals of Applying SmartCloud

IBM announces unusual SmartCloud capabilities, Partnership With Nirvanix | killexams.com actual Questions and Pass4sure dumps

IBM has nowadays increased its cloud computing features for enterprise with the launch of recent IBM SmartCloud capabilities. These unusual offerings include SmartCloud utility features, IBM’s unusual PaaS for enterprise, a portfolio of hardware and software known as SmartCloud basis, and SmartCloud Ecosystem, which comprises unusual features for IBM companions and ISVs.

The business plans to inspirit around 200 million clients via the conclusion of 2012.

IBM says that it has ported SAP, ERP and entire database functions to its SmartCloud platform. With its new services, it may possibly now automate labor-intensive tasks linked to operating SAP within the cloud, specifically SAP cloning, refreshes and patching. In some circumstances, IBM says the time rate reductions can vanish from months or weeks to days or hours, counting on the assignment.

also introduced nowadays is a unusual partnership with Nirvanix, a cloud storage company. Going forward, Nirvanix’s cloud storage know-how should be integrated into IBM’s SmartCloud enterprise storage features, enabling consumers to upload information of any dimension, anyplace in the world, and access them from any place. The storage-as-a-provider providing can champion millions of clients, billions of objects and exabytes of records.

in the meantime, IBM’s unusual platform-as-a-carrier offering, SmartCloud application functions (SCAS) will launch into beta this yr (q4), offering enterprise–grade protection, open Java and go-platform champion with no vendor lock-in, and a comprehensive set of utility infrastructure and managed services to allow construction and deployment of purposes to the cloud. It will avoid on IBM’s SmartCloud commercial enterprise and commercial enterprise+ – the business-type infrastructure-as-a-platform peculiarly designed to avoid commercial enterprise workloads at dedicated SLAs (provider degree agreements). IBM SmartCloud enterprise+ is attainable within the U.S., and will be deployed international by way of the conclusion of 2012.

ultimately, the unusual SmartCloud basis family unit of deepest cloud options goals to champion agencies promptly design and install inner most cloud environments, and includes SmartCloud Entry, prepackaged private cloud software, plus SmartCloud provisioning and monitoring application.


IBM Evolves from On exact to SmartCloud | killexams.com actual Questions and Pass4sure dumps

domestic   →   ERP   →   IBM Evolves from On exact to SmartCloud Posted October 12, 2011 by way of Sean Michael Kerner     remarks

New IBM application features for cloud consist of middleware, DB2, SAP functions and CRM.

IBM (NYSE: IBM) is rolling out a brand unusual set of SmartCloud capabilities and application, offering unusual alternatives for companies to sprint their purposes to a cloud mannequin.

the unusual offerings consist of the debut of SmartCloud commercial enterprise 2.0, which is a Platform-as-a-provider (PaaS) providing. the brand unusual SmartCloud will likewise allow IBM DB2 database-as-a-provider as well other IBM functions. IBM isn't just enabling its cloud for IBM software; the SmartCloud likewise has a service for SAP ERP functions.

"This announcement takes their cloud capabilities to the next degree," Lauren States, VP and CTO of Cloud Computing at IBM, told InternetNews.com. "We're adding means to the portfolio for software edifice and deployment in the cloud with SmartCloud application services."

States referred to SmartCloud application services is IBM's PaaS for the commercial enterprise. She mentioned that initially the software services are concentrated on Java applications and transactional database functions with IBM's DB2. there's additionally an SAP purposes carrier that supplies SAP as a packaged app that will likewise be deployed and administered within the cloud.

"We're climb with what their core customers employ with their know-how and we'll be edifice that out with other capabilities over time," States noted.

remaining week, Oracle announced its personal public cloud providing, including a database-as-a-carrier providing. States talked about IBM's platform is entire about exposing IBM's middleware capabilities as a service. She delivered that programmers who are writing applications for the cloud can simply name the provider, whether or not it's database or a further service, and that they will not luxuriate in to be troubled concerning the underlying complexity of the stack.

The SmartCloud platform is being delivered on a Linux infrastructure with future plans to expand with windows and IBM's AIX Unix. IBM is the employ of KVM and pink Hat as the underlying technology seller platform. The platform can likewise be used to convey cloud enterprise functions, together with cloud ERP.

IBM is likewise introducing a SmartCloud basis application portfolio for groups trying to deploy on-premise.

"a lot of customers are just getting started with cloud and that they want to seat of attention on the merits of virtualization, management and automation for operational effectivity," States mentioned. "This SmartCloud foundation fills a niche in their on-ramp to the cloud and it could actually set the basis for customers that at eventual want to find to self-provider, pay-as-you-go infrastructure."

IBM's cloud push is likewise being prolonged to IBM's latest On exact hosted consumer base. States referred to that IBM already has a huge application on exact internet hosting business. IBM introduced in April that the blueprint became to supply On exact purchasers with cloud capabilities.

"it be their intent to deliver a cloud enabled environment inside their software on exact internet hosting business for those customers that necessity to leverage that operational effectivity," States spoke of.

IBM additionally announced a collaboration with SugarCRM to fabricate its client relationship management (CRM) items accessible on the IBM SmartCloud business. "valued clientele can now hold abilities of advanced CRM solutions, deployable in a import number of minutes, whereas reaching entire of the benefits of a non-public cloud ambiance," IBM pointed out in an announcement.

Sean Michael Kerner is a senior editor at InternetNews.com, the information provider of internet.com, the network for technology professionals.


IBM Unveils unusual ‘DevOps’ CLM tools for the Cloud | killexams.com actual Questions and Pass4sure dumps

IBM the day past unveiled unusual software and features designed to aid clients streamline the application development lifecycle, or what IBM calls “building operations,” or simply DevOps. As allotment of the announcement, which turned into made on the annual Rational Collaborate convention in Florida, parts of Rational’s Collaborative Lifecycle administration (CLM) suite may be made obtainable as a DevOps appliance hosted in IBM’s SmartCloud.

The CLM suite, which IBM unveiled ultimately 12 months’s Collaborate reveal, is built on IBM’s open construction platform, known as Jazz, and combines three Rational products, together with necessities Composer, crew live performance, and quality manager, in a unique suite that IBM says is easier to buy, deploy, and employ than separately cobbling the items collectively.

massive Blue yesterday introduced five unusual CLM products and services as allotment of its push into DevOps for the cloud. It likewise introduced unusual cell capabilities in its CLM suite.

the primary DevOps for the Cloud providing bears an unwieldy name: “IBM Rational respond for Collaborative Lifecycle management on IBM SmartCloud enterprise.” This offering is really a slice of IBM’s SmartCloud commercial enterprise that a consumer can employ as a edifice and examine atmosphere. SmartCloud enterprise, you will remember, is a public infrastructure as a service (IaaS) offering in line with X86 hardware and the Linux OS. SmartCloud enterprise+ helps energy techniques environments, but now not IBM i.

the brand unusual IBM SmartCloud application functions (SCAS) platform as a service (PaaS) providing that changed into launched in October 2011 additionally has a role in IBM’s cloud-based mostly DevOps plans. IBM sees SCAS (which comprises a Linux OS, WebSphere became, DB2 database, and SAP purposes) giving consumers a location the location they can execute building, build, check, and bring actions.

IBM additionally announced the SmartCloud for executive development and notice at various Platform. This providing will give executive organizations a way to access the CLM suite from a scalable, hosted environment. IBM says this offering will conform to the Federal tips safety management Act (FISMA).

additionally playing into the DevOps cloud is SmartCloud perpetual delivery, which IBM describes as a set of “choicest practice patterns” designed to aid shoppers employ CLM tools and IBM’s SmartCloud Provisioning application to manipulate the lifecycle of cloud-based mostly functions. SmartCloud continuous birth was at the climb unveiled in March, and is at present in beta.

The SmartCloud application efficiency management offering provides purchasers with entry to Tivoli monitoring and management tools for making improvements to the performance of cloud purposes.

On the cell entrance, IBM introduced that its CLM suite can now toil with the IBM cell foundation. The cell foundation, if you neglected it, combines three tools, together with the IBM Worklight HTML5 mobile software edifice and runtime environment; the IBM Endpoint supervisor device; and WebSphere cast iron for integration.

the unusual business cellular edifice providing combines CLM, the cellular groundwork, and a yoke of other Rational tools, including the unusual Rational Developer for vigour techniques edition 8.5 liberate (which that you could examine greater about here), Rational Developer for system z 8.5, Rational application Developer 8.5, and the Android SDK and Emulator. IBM says that with the aid of integrating entire these items, consumers can hope to velocity up the technique of designing, constructing, checking out, and deploying business cellular apps, and doing so in a cozy and compliant manner.

It’s a wide, wily cloud world obtainable, and IBM is determined to champion purchasers reduce throughout the litter and control their cloud utility edifice activities. “nowadays’s business problem is the way to handle both the necessity for speedy birth and ample handle in the utility edifice system,” Dr. Kristof Kloeckner, common manager of IBM Rational, says in an announcement. “We necessity to equilibrium the necessity for velocity and agility with more suitable governance to manipulate saturate and high-quality, obtain regulatory compliance, be positive protection, and luxuriate in some degree of monetary predictability.”

connected studies

IBM Puffs Up unusual Public, inner most SmartCloud Releases

IBM Ships unusual Collaborative Lifecycle administration Suite

IBM Consolidates Rational crew live performance items, Simplifies Licensing

IBM Unveils change administration utility for device i

                     post this chronicle to del.icio.us               submit this chronicle to Digg    publish this chronicle to Slashdot


While it is difficult errand to pick solid certification questions/answers assets regarding review, reputation and validity since individuals find sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets as for exam dumps update and validity. The greater allotment of other's sham report objection customers further to us for the brain dumps and pass their exams cheerfully and effortlessly. They never compact on their review, reputation and quality because killexams review, killexams reputation and killexams customer certitude is imperative to us. Extraordinarily they deal with killexams.com review, killexams.com reputation, killexams.com sham report grievance, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. On the off haphazard that you behold any erroneous report posted by their rivals with the name killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com protestation or something like this, simply remember there are constantly terrible individuals harming reputation of valid administrations because of their advantages. There are a noteworthy many fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams questions, killexams exam simulator. Visit Killexams.com, their sample questions and test brain dumps, their exam simulator and you will realize that killexams.com is the best brain dumps site.

Back to Braindumps Menu


000-274 exam prep | 000-453 questions and answers | 350-022 study guide | NS0-151 free pdf download | C4090-452 test prep | COG-622 study guide | MSC-122 questions and answers | HP0-022 braindumps | 300-101 practice questions | 1Z0-028 practice questions | C2140-842 mock exam | 000-591 pdf download | MOPF brain dumps | BCCPA VCE | 9A0-035 bootcamp | C2150-609 exam questions | PACE braindumps | 2V0-622D dumps questions | C2180-529 actual questions | 700-104 braindumps |


Pass4sure C2010-659 Fundamentals of Applying SmartCloud Control Desk V1 exam braindumps with actual questions and practice software.
Are you looking for IBM C2010-659 Dumps of actual questions for the Fundamentals of Applying SmartCloud Control Desk V1 Exam prep? They provide most updated and quality C2010-659 Dumps. Detail is at http://killexams.com/pass4sure/exam-detail/C2010-659. They luxuriate in compiled a database of C2010-659 Dumps from actual exams in order to let you prepare and pass C2010-659 exam on the first attempt. Just memorize their and relax. You will pass the exam.

We luxuriate in Tested and Approved C2010-659 Exam dumps. killexams.com provides the foremost distinctive and latest C2010-659 braindumps that much comprise entire s you need. With the guide of their C2010-659 exam dumps, you ought to not squander your risk on spending time on reference books and nearly luxuriate in to be compelled to expend 10-20 hours to ace their C2010-659 actual Questions and Answers. Whats larger, they luxuriate in an approach to proffer you with PDF Version and Exam Simulator Version test Questions and Answers. For Exam Simulator Version dumps, the candidates mimic the IBM C2010-659 exam in an exceedingly actual test atmosphere. killexams.com Discount Coupons and Promo Codes are as under; WC2017 : 60% Discount Coupon for entire exam on website PROF17 : 10% Discount Coupon for Orders additional than $69 DEAL17 : 15% Discount Coupon for Orders additional than $99 SEPSPECIAL : 10% Special Discount Coupon for entire Orders Click http://killexams.com/pass4sure/exam-detail/C2010-659

killexams.com enables a great number of candidates to pass the exams and find their certifications. They luxuriate in an immense number of powerful overviews. Their dumps are strong, sensible, updated and of genuinely best quality to vanquish the inconveniences of any IT certifications. killexams.com exam dumps are latest updated in exceedingly rout route on touchstone start and material is released discontinuously. Latest killexams.com dumps are available in testing centers with whom they are keeping up their relationship to find latest material.

The killexams.com exam questions for C2010-659 Fundamentals of Applying SmartCloud Control Desk V1 exam is essentially in perspective of two accessible game plans, PDF and practice test. PDF record passes on entire the exam questions, answers which makes your arranging less persevering. While the practice test are the complimentary component in the exam thing. Which serves to self-overview your progress. The appraisal mechanical assembly likewise includes your feeble locales, where you necessity to attach more attempt with the objective that you can ameliorate each one of your stresses.

killexams.com propound you to must attempt its free demo, you will behold the common UI and moreover you will believe that its simple to adjust the prep mode. Regardless, guarantee that, the actual C2010-659 exam has a bigger number of questions than the sample exam. In case, you are appeased with its demo then you can purchase the actual C2010-659 exam thing. killexams.com offers you three months free updates of C2010-659 Fundamentals of Applying SmartCloud Control Desk V1 exam questions. Their accreditation group is always open at back conclude who updates the material as and when required.

killexams.com Huge Discount Coupons and Promo Codes are as under;
WC2017: 60% Discount Coupon for entire exams on website
PROF17: 10% Discount Coupon for Orders greater than $69
DEAL17: 15% Discount Coupon for Orders greater than $99
DECSPECIAL: 10% Special Discount Coupon for entire Orders


C2010-659 Practice Test | C2010-659 examcollection | C2010-659 VCE | C2010-659 study guide | C2010-659 practice exam | C2010-659 cram


Killexams AFE dumps | Killexams LCAC dump | Killexams 2B0-103 free pdf | Killexams CSET practice exam | Killexams M6040-520 questions and answers | Killexams 000-575 practice test | Killexams HP0-J40 study guide | Killexams 3000-2 brain dumps | Killexams NSE7 exam prep | Killexams 000-922 actual questions | Killexams 000-642 free pdf | Killexams 9L0-402 questions and answers | Killexams 648-247 braindumps | Killexams C9560-568 braindumps | Killexams 00M-244 actual questions | Killexams 1T6-303 braindumps | Killexams NailTech braindumps | Killexams HP2-K27 brain dumps | Killexams EVP-101 study guide | Killexams 922-100 test prep |


killexams.com huge List of Exam Braindumps

View Complete list of Killexams.com Brain dumps


Killexams PRF study guide | Killexams 9A0-310 questions and answers | Killexams 310-345 examcollection | Killexams 000-331 brain dumps | Killexams 920-262 study guide | Killexams C9520-422 free pdf | Killexams 3X0-102 sample test | Killexams ST0-303 exam prep | Killexams C2010-507 braindumps | Killexams 3M0-701 practice exam | Killexams 000-858 dumps questions | Killexams 300-375 actual questions | Killexams PEGACSSA practice test | Killexams 646-392 practice test | Killexams 000-M46 questions and answers | Killexams 1Z0-435 test questions | Killexams HP0-311 test prep | Killexams 050-v66-SERCMS02 free pdf | Killexams 70-742 actual questions | Killexams EADA10 bootcamp |


Fundamentals of Applying SmartCloud Control Desk V1

Pass 4 positive C2010-659 dumps | Killexams.com C2010-659 actual questions | http://tractaricurteadearges.ro/

From Gold Bar to Joshua Tree | killexams.com actual questions and Pass4sure dumps

Warning. A lot of climbing talk ahead.

The next morning, they woke up before 9, ate some cereal with mixed fruits, and headed out with some crash pads. Chad, Brooke, Josh, Wendy and I drove about 30 minutes out into the far desert and parked at the Hidden Valley Picnic belt parking lot (big mistake — there’s a parking lot at the Hidden Valley campsite literally across the street).

Just one of the rock formations at Joshua Tree.

(Side note, I grew up in the tall desert. It doesn’t notice as stunning or resplendent as this.)

We got lost for a bit and took a long hike around from the west side but eventually institute a VERY simple (listed) V1, that was honestly more like a V0 with a very short top out. Maybe they identified the boulder wrong.

Behind us was White Rastafarian. withhold in mind I luxuriate in no awe doing any V2s at the gym. They’re usually require some technical moves but for the most part, they’re easily doable. White Rastafarian does not supervene suit with that trend: the top-out of the boulder is 25 feet tall and has a crux about 20 feet up that requires a span from one crack to another.

I ended up being able to fabricate it to a juggy hold about halfway through the problem before I called it quits and decided not to risk injury.

The elusive White Rastafarian. Objects are smaller than they appear — the top of this boulder is 25 feet up!

After this, they headed to Pinhead a smallish boulder about 50 yards or so from White Rastafarian. This had a yoke of noteworthy routes.

I was able to top out on this route, but due to my poverty-stricken choice in footing, I slipped and fell, despite grabbing the juggy topout. I got a shallow scrape near my perquisite thumb, and decided forfeit the route in the interest of taping it up and finding something easier. (I now regret not trying the route again after Chad and the others tried it.)

Bandaged up.

I was, however, able to complete the Pinhead Traverse (V0-).

Brooke on the crux of the Pinhead Traverse. Wendy ‘scends the Pinhead Traverse (V0-). Chad using a Double Gaston perquisite before he ‘scends Pinhead.

Chad showed us this route that he institute northeast of Pinhead. I’d attach the gym grading as a V2 or maybe V2+, but outdoors, it’s likely a V0.

Chad’s V0. Josh and Brooke spotting.

I didn’t try it — I wanted to deliver my energy for their eventual planned route for the day: Hobbit cavity Offwidth.

This offwidth boulder was tucked behind some brush and more rocks, and when they got there, Josh and Chad began to scramble up some surrounding rocks in the area. Wendy took a stab at Patina, a friction V1.I honestly had never really tried a friction climb, and the closest I’d seen at a climbing gym were labeled as VHards…

Wendy makes progress on Patina.

Hobbit cavity is obviously an “Offwidth” problem (see this video for reference on what the offwidth climb would notice like), but I decided to achieve a lieback approach. I didn’t want to avoid the risk of slipping and jamming my carcass into the crack — I’ve seen 127 Hours and I’d rather not luxuriate in a similar situation of getting stuck between two rocks.

This problem was a noteworthy learning experience, but I’ll just bundle in that lesson into the various other lessons I took away from that day’s climbing:1. Learn to sprint your feet alongside your hands. This is something that I often instruct to newbie climbers and I needed to re-teach myself when climbing outdoors.2. Feel the rock before attempting to finish it. Unlike gym routes, the routes outdoors don’t luxuriate in colored tape or markings designating where to vanish next. You can’t behold that a hold is a sloper. A shelf or crack may not be consistently juggy throughout. This is likewise something that I disclose unusual climbers when they send me pictures of a route asking, “What achieve I achieve next?” I can only speculate so much. The best remedy is to just vanish out there and try climbing the rock.3. be prepared to fabricate risky moves. I consider this is a bit hypocritical on my part. On one hand, I promised myself that I wouldn’t injure myself outdoors as to not destroy my trip…but conversely I likewise realized that I would likewise forestall myself from performing moves that were either extremely painful, or performed an action that would require a quick recovery rather than a slow, systematic approach. It made me wonder — how achieve climbers really ameliorate their grade at the gym? achieve they just find stalwart enough (either through repetitive training or focused exercises) to complete higher grades with ease or achieve they actually suffer the stitch of making uncomfortable moves and just live with it? I consider the perquisite respond here is that it’s a equilibrium of the two, but I’ve been ignoring the latter phenomena — when I gain an uncomfortable move, I often convoke it quits and then drop down and reassess. Is that what’s selling myself short? achieve I awe a minute of stitch of which I could possibly toil through and behold success beyond the horizon?

In the end, I feel like this boils down to a simple principle: remember your fundamentals. Of course, there are problems outdoors that can’t be easily re-created indoors, and there are different risks to take, but I felt that a lot of problem points that emerged when climbing outdoors simply stemmed from losing my frigid and remembering my fundamentals even though it seemed like I was presented with a totally different context.

When they left the park that day, Wendy got several messages from her family and informed us that she needed to head back home for an emergency. As a matter of privacy, I’ll spare the details.

When they got home, they relaxed for a bit, and as the evening emerged, they had some pasta, sat around a fire pit, and chatted.A crescent moon appeared in the distance, under the stars, and above the silhouette of the mountains. It was honestly one of the most resplendent scenes I had ever witnessed, and unfortunately I don’t luxuriate in a picture of it. entire I can achieve is report it with words and you’ll just luxuriate in to believe me.

Later, Chad pointed out the International Space Station passing by, which was a luminous light that emerged from the west and traveled in a line slowly to the east. Although it looked like nothing more than a steady star pathetic across the sky, it was exciting and they entire chatted about it for quite some time.

Afterwards, Chad brought out his telescope and they got to behold Jupiter and some star clusters. Wendy taught me how to hold long-exposure night photographs, but the light pollution from town definitely caused the pictures to be less than perfect. I wish I could practice this more, but I didn’t bring a tripod, and likewise Seattle isn’t exactly primed for limpid skies.

Not so noteworthy for my first long exposure, but it’ll achieve for now. Wendy likewise made us s’mores. notice at that presentation!

We went inside afterwards, then played some Monikers. Chad asked if I could cast together an improv DnD session while Wendy and Vincent called it a night.It was fun, and I wish I could achieve more sessions like that.

The house before playing Monikers. A bit blurry, but maybe usurp given the circumstances…

Why the Harper Majority is a Step Back for Science – Let Us import the Ways | killexams.com actual questions and Pass4sure dumps

This is a guest post by David Ng, a science literacy academic at the Michael Smith Laboratories of the University of British Columbia.

In case you missed it, eventual night saw the Canada election deliver a Conservative majority. It was an effulgent and historic vote for a variety of reasons, but the bottom line is that now the Harper government is in a position to achieve pretty much as it pleases, given its position of majority power in both the House of Commons and the Canadian Senate.

As is the norm for any democratic action, this is valid and cross depending on your perspective and ideals. Those who fabricate their homes in the business or economic front generally behold the result as a positive; whereas those who value fairness, ethical government practices, and sociable issues attend to notice upon the election as a daunting and frustrating setback. In this mix, however, is the scientific point of view. And speaking as a Canadian scientist, I want to employ this space to fabricate the case that entire things being considered, this is a fundamentally cross minute in history for Canadian science.

To achieve this, let’s access how the Harper government (not the “Government of Canada” as it was once officially called) has performed so far (in the science context anyway).

And let’s quarrel for this in a rational way. They are after entire scientific folk. In fact, let’s apply the valid worn rubric of looking at the claim, providing a reason, and then presenting the evidence for this stance.

First up is their claim: let’s just vanish with something direct:

The Harper Government is cross for Science.

As for coming up with a reason, it’s actually fairly straightforward. Here, we’ve seen repeated examples that would demonstrate a limpid want of understanding science culture, as well as actions that often undermine the very notion of scientific literacy. Sometimes, you find the sense that science just isn’t vital to this government, and on occasion it even feels downright inconsequential.

But, of course, this verbose understanding can’t stand on its own verbiage. They necessity concrete evidence for their claim, and to achieve this, it’s probably easiest to focus on a number of key points that demonstrate Harper’s modus operandi.

Point 1. The Harper government is not terribly scientifically literate.

There’s a few examples of this (also behold point 2), but let’s simply draw attention to the appointment of a Minister of Industry, Science and Technology who waffles on the science of evolution. In case you don’t know his name, it’s Gary Goodyear: and in essence, his role in government is meant to be the primary driver on pushing and representing how science is funded, courted, guided, and basically done in Canada. Although an architect of many a slice to science funding in times that arguably necessity more scientific innovation (see 4 for more), he was and quiet is illustrious as a controversial device when in 2009, the Globe and Mail asked him to partake his stance regarding evolution. To this, he replied, “I’m a Christian, and I don’t consider anybody asking a question about my religion is appropriate.”

Now from a scientific point of view, this kind of statement is mildly troubling – you would hope that at least the Minister representing science would luxuriate in more eloquent words to drawl on this subject. Unfortunately, this wasn’t the case as illustrated with his further comments on the matter when pressed again during a television interview. During this incident, he chose to proclaim his faith in evolution, but continued with this very odd and ludicrous description of what evolution is:

“We are evolving, every year, every decade. That’s a fact. Whether it’s to the intensity of the sun, whether it’s to, as a chiropractor, walking on cement versus anything else, whether it’s running shoes or tall heels, of course, they are evolving to their environment.”

2. The Harper government has managed to fabricate Climate Change science an ideological issue.

You’ve actually seen a lot of this already in American politics, but nowadays there’s likewise a Canadian version. Here’s how it works:

In general, science is fairly particular about the way it is done. The mode is built to thrive on objectivity and it is ultimately based on the things they see, record, and analyze. It isn’t perfect, since the concept of a paradigm can exert influence, but the evidence it builds on quiet has to meet some pretty tough criteria – certainly much more stringent than other epistemologies, or other ways of knowing. attach another way, scientific evidence is not suppose to be swayed by ideological or partisan lines.

Despite this, Harper’s politics luxuriate in warped the science of climate change into one of partisan debate. entire other Canadian political parties hold the science at physiognomy value, and build from it. Not so with the Conservatives. This is inherently disrespectful to the scientific community, as it suggests that they can fabricate decisions concerning climate change in a location where scientific literacy has no currency, whereby the overwhelming scientific consensus is treated as nothing more than an effulgent and suspicious footnote.

As a result, Harper runs the country on the pretense of whether one can faith or distrust the scientific evidence, without actually debating the actual technical strengths and weaknesses of the climate science data currently presented. Harper runs the country based on messages that economically sound promising, but are environmentally unsustainable, and luxuriate in stalwart repercussions which conveniently will hold shape long after he is retired. Above all, he places an accent on nurturing a subtle shape of climate change denialism and has made it allotment of the conservative ideology. From a scientist’s point of view, this is probably not the best way to formulate vital policies – on “feelings” as combat to concrete evidence. In essence, they can drawl that I may not be a betting man: but if I was, I’m pretty positive that the scientific community is the best location to find their odds.

Now, one might quarrel that this is not Harper’s stance at all. It would issue that the official hold would proclaim the government’s official backing of the “fundamentals of climate change science.” However, as always is the case, actions talk louder than words. As evidence of this, you only necessity to withhold track of the Harper’s record on climate change. Since obtaining its first minority government in 2006, the Conservatives luxuriate in essentially moved away from Canada’s commitment to Kyoto, and has repeatedly undermine climate change talks (to the point of being consistent winners of the “Fossil of the Day” award), allotment of which involves the perpetual setting up of disappointing emission targets.

In 2009 the goal was to slice carbon emissions by 20% below 2006 levels by 2020; an equivalent of 3% below 1990 levels by 2020. The goal was later changed in early 2010 to 17% of 2005 levels by 2020; an equivalent of 2.5% above 1990 levels.

The three most populous provinces disagree with the federal government goal and announced more ambitious targets on their jurisdictions. Quebec, Ontario and British Columbia announced respectively 20%, 15% and 14% reduction target below their 1990 levels while Alberta is expecting a 58% increase in emissions. (Wikipedia, April 2011)

More troubling, is that Harper appears to not luxuriate in any qualms about pushing his agenda in any way possible, and does so in a way that draws limpid distinctions between party lines. In particular, is his egregious misuse of Senate power to vanish against the democratic passing of a Climate Change Bill (Bill C-311).

Here, a quick lesson in Canadian government procedures might help. Essentially, when Canadian laws or Bills are attach on the table, they necessity to vanish through a vote in the House of Commons. This is represented by elected members of government, such that the voting here is inherently meant to depict the “will of the people.” However, if passed, the law then needs to vanish through the Canadian Senate. This flat of government is suppose to reflect a location of “sober second thought,” but historically, the Senate very rarely goes against the decisions made in the House of Commons. This is because Senate members are appointed, and therefore in principle are there to quiet respect the democratic underpinning of the House of Commons’ vote. However, in December 2008, Harper filled 18 vacant Senate spots with Conservative appointments, and has used this Senate majority in undemocratic ways – including the killing of the Climate Change Bill.

Still, there are other ways to compel an ideology along: which brings us to point number three.

3. The Harper government has demonstrated a willingness to “muzzle” science.

In 2010, the release of Environment Canada documents showed that unusual media rules introduced by the Harper Government in 2007, with the train to control the ability for Federal climate scientists to interact with media, had been amenable for what many of these scientists luxuriate in called a “muzzling” effect.

“Scientists luxuriate in noticed a major reduction in the number of requests, particularly from tall profile media, who often luxuriate in same-day deadlines,” said the Environment Canada document. “Media coverage of climate change science, their most high-profile issue, has been reduced by over 80 per cent.”

The analysis reviewed the impact of a unusual federal communications policy at Environment Canada, which required senior federal scientists to hunt authorization from the government prior to giving interviews.

The document suggests the unusual communications policy has practically eliminated senior federal scientists from media coverage of climate-change science issues, leaving them frustrated that the government was trying to “muzzle” them. (Montreal Gazette, March 15, 2010)

This facet of Harper’s strategy is especially troubling. Science, as a whole, is a venture that best works when there is fluidity and an openness in how information is shared. Whether that is within the scientific community in the shape of expert peer review, or back and forth between scientists and the general public or the policy makers as a dialogue of civic consequence, there is simply no commendable understanding for this shape of control. It should be obvious that discussions on Climate Change, which has obvious public importance, things shouldn’t be avoid like a corporation protecting its secrets and/or hiding information that veers away from the desired message.

4. The Harper Government is out of finger with science culture: scientists are driven by many things, and not always by the industry/business/corporate mentality.

Over the eventual yoke years, we’ve seen examples where the Harper Government has consistently pushed research towards a cumbersome accent for applied sciences and industry, often at the expense of basic science. Whether this is via funding cuts to granting agencies such as the Natural Sciences and Engineering Research Council (a bastion of basic science research), diverting such monies towards projects where business-related objectives are encouraged, or via restructuring of the National Research Council such that industry-related projects are given priorities, there’s definitely a mode to his ways. Overall, this indicates a general ignorance of how scientific progress works – that is, it is almost always the discoveries born from basic research that fuel the future innovation necessary for applied benefits. attach another way, if Harper continues on this track to give himself quick political gain, he does so at the expense of future Canadian science. Even a miniature lull in basic research in the present could result in a significant lull in applied and economic potentials in the future.

As well, this constant patronage towards the business side of science likewise doesn’t necessarily reflect the intentions of the scientists themselves. Money and economics may be desirable things for scientists, but most often there are other stronger motivations at stake – including an aspiration to bring about positive change in the world, as well as plain worn intellectual curiosity.

An sample of Harper’s willingness to always give credence to the corporate line, is his Government’s poverty-stricken handling of the recently diposed Bill C-393. Essentially, this is an episode where cross politics trumped valid science. The valid science in this case is the fact that there are very effectual antiretroviral drug out there, which fabricate HIV/AIDS a treatable disorder. Unfortunately, these are mostly priced too tall for individuals in developing countries – countries where unnecessary death from HIV/AIDS is catastrophically high. The cross politics concerns a frustrating sequence of events that saw a Bill (C-393), designed to fairly and with monitoring facilitate production of generic drugs, find passed in the House of Commons (i.e. democratically given the green light); then was taken to Senate, where it was deliberately stalled for five days, in an atmosphere where delusive information provided by the pharmaceutical industry was being distributed to the Tory Senators; such that it was ultimately killed by default when the unusual election was called. The fact that the understanding for this was ultimately because of the Harper’s Government willingness to patronize sizable Pharma is extremely galling, especially when so many lives were literally at stake.

Conclusion

It’s vital to note that science culture isn’t the only thing that drives a civil society. However, as a conduit for reasoned discourse and pertinent information that affects local and global concerns, it’s obvious that science must not be taken for granted. Based on eventual night’s election results, they luxuriate in every understanding to worry about the Conservative majority, as the Harper Government has repeatedly demonstrated past activities that not only hold science for granted, but handle it with a shape of contempt. The Harper government has consistently ignored whatever sound utility the scientific endeavor can provide, and by doing so, has attach the future of Canadian science at risk, as well as the elements of society that would luxuriate in otherwise benefited from it.

In the end, this means that they must watch the actions of this Harper Government more closely; and to be vocal, to be active, and to achieve their best to hold them to account for their actions. Democracy has given Harper a mandate to govern as he sees fit, and for this there should be an constituent of respect as well as an constituent of opportunity. However, Harper should not forget that Canadian democracy is ultimately driven by the people of Canada. For that reason, I will be watching you closely. Scientists will be watching you closely. Canadians will be watching you closely.

David Ng is a science literacy academic at the Michael Smith Laboratories of the University of British Columbia. He has written essays for the Walrus, humour for McSweeney’s, commentary for Boingboing, and is now trying to learn more about Access to Medicine issues at the My Rights Versus Yours Blog. You can supervene him on twitter @dnghub. If you’re a Canadian reader, he likewise encourages you to check out aidsaction.ca to note that almost entire conservatives quiet align themselves with sizable Pharma’s stance on Access to Medicine issues. Why not send them an email to fabricate positive they know exactly how you feel?


The Regulatory Strategist Toolbox: Clinical Endpoint Analysis Tools | killexams.com actual questions and Pass4sure dumps

One of the critical parts of assembling a product’s “Strategy Playbook” or “Clinical development Plan” is the researching and planning of clinical endpoints. This article discusses how to research endpoints, including tools to research them, how to organize the information and how to present the intelligence back to the team.

Endpoints are measures intended to reflect the effects (efficacy endpoints) or safety (safety endpoints) of a drug or device. They include assessments of clinical events (e.g., stroke, pulmonary exacerbation, venous thromboembolism), outcomes (e.g., what a final result of treatment long term, mortality, tumor resolution, cure of disease, remission), patient symptoms (e.g., pain, dyspnea, depression), measures of function (e.g., ability to walk or exercise), adverse events or surrogates of these effects or symptoms; clinical outcomes are considered the most dependable endpoint.1 One of the critical parts of the assembling either a product’s “Strategy Playbook” or “Clinical development Plan” is the researching and planning of endpoints from phase 1 through 3, including navigating through FDA’s understanding and interpretation of the laws and definitions (Table 1). 

Defining Efficacy Endpoints

Defining efficacy and their measurement through endpoints has been a dynamic process since the US 1962 Kefauver Harris Amendment to the Federal Food, Drug, and Cosmetic Act (FD&C Act), which was the first time a demonstration of efficacy (and endpoints to measure efficacy) was required.2,3 After the amendment, FDA spent the next decade defining, discussing, evolving and defending Sponsors’ lawsuits to arrive at what efficacy expectations should include (and some drawl the process is quiet ongoing).4

Prior to the 1962 Kefauver Harris Amendment:

  • efficacy was not clearly defined, safety of the product was relied upon
  • FDA was not involved in the definition of efficacy or claims of efficacy for products
  • companies would define efficacy (and subsequent endpoints) differently for similar products and both companies would claim efficacy of the product
  • companies let the individual physicians define efficacy and endpoints based on their patient population and theme interpretation (which would be combined as case studies into a marketing application resulting in many different endpoints used in the selfsame study).
  • FDA’s definition and struggles to define efficacy served as a model for other regulatory agencies to adopt and employ when formally establishing their own efficacy requirements; hence, the US focus in this article, but this information can be used in planning global trials with consultation of individual country regulations and guidance.

    Why are endpoints needed?

    Sound evidence of effectiveness is a crucial component of any regulatory agency’s benefit-risk assessment of a unusual product or employ (i.e., a unusual indication). The necessity for an endpoint to measure the effectiveness of a drug stems from FDA’s necessity for substantial evidence, specifically called for in the 1962 Kefauver Harris Amendment and in 21 CFR 314.50 5.iii.v which requires that a marketing application contain, “data demonstrating substantial evidence of effectiveness for the claimed indications.” Substantial evidence was defined in section 505(d) of the FD&C Act as “evidence consisting of adequate and well-controlled investigations, including clinical investigations by experts qualified by scientific training and suffer to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will luxuriate in the effect it purports or is represented to luxuriate in under the conditions of employ prescribed, recommended or suggested in the labeling or proposed labeling hereof.”5

    An adequate and well controlled (A&WC) study is defined in 21 CFR 314.126.b as a ordeal containing (summarized):

  • clear statement of objectives
  • methods of analysis which are adequate to assess the effects of the drug
  • use of a valid study design
  • defined patient population
  • randomization of patients
  • minimization of bias
  • Valid or Accepted Endpoints: the methods of assessment of subjects' response are well-defined and reliable. The protocol for the study and the report of results should interpret the variables measured, the methods of observation and criteria used to assess response.
  • Clinical Benefit

    FDA would like efficacy endpoints, if not already issued in a guidance document, to incorporate the mantra of “feels, functions or survive” which is collectively defined as clinical benefit. Clinical capitalize is a clinically meaningful effect of an intervention, i.e., a positive effect on how an individual:

  • feels (e.g., symptom relief)
  • functions (e.g., improved mobility, improvement or leisurely in the progression of a disease or condition)
  • survives (e.g.,  time in leisurely to death in comparison to a natural history cohort)
  • Clinical capitalize should be meaningful and understandable to prescribers and patients and can be measured directly or indirectly (indirect assessment needs justification for its value as a replacement for how patients survive, feel or function).6,7

    Clinical capitalize Endpoints that luxuriate in supported drug approval luxuriate in included vital clinical outcomes (e.g., increased survival, symptomatic improvement), but likewise luxuriate in included effects on established (validated) surrogate endpoints (e.g., blood pressure, serum cholesterol).8,9

    The caveat here is if there is no instrument to measure how a patient “feels” or “functions,” one’s company might necessity to develop and validate a patient reported outcome to capture and measure this.

    Table 1. Overview of the practicable Clinical ordeal Endpoints. Term Definition Endpoint

    An endpoint is a primary or secondary outcome used to referee the effectiveness of a treatment; it is a precisely defined variable intended to reflect an outcome of interest that is statistically analyzed to address a particular research question. Synonyms include: outcome, variable, parameter or marker.

    An endpoint typically specifies the kind of assessments made, the timing of those assessments, the assessment tools used and possibly other details, as applicable, such as how multiple assessments within an individual are to be combined.10

    An sample of endpoints are survival, improvements in quality of life, relief of symptoms and disappearance of the tumor.11

    Well-defined and dependable (21CFR 314.126)

    Appropriate for the target population

    Appropriate for the target indication

    Adequate measurement properties, e.g., content validity: PRO development relies on patient input to champion content validity12

    Using conclude points that luxuriate in already been approved by the regulatory authority makes the most sense, but if a unusual endpoint is being used, then it is necessary to prove that this endpoint is a valid measure of drug success.

    Primary Endpoint Primary endpoints means the outcome or event that most accurately measures the capitalize of the therapy/drug/intervention being studied (efficacy); this is the most clinically vital endpoint. This is the main question the sponsor is most interested in answering and one that is capable of being answered (i.e., “Does the intervention alter mortality rates or change baseline blood pressure, the number of deaths, the dissimilarity in survival between the treatment group and the control group, disease progression or death). There is usually only one primary endpoint. Most of entire the primary endpoint needs to be clinically meaningful and recognized by regulators as being clinically meaningful or parley clinical capitalize (for unusual indications this can be a challenge) and should reflect the accepted norms and standards in the pertinent territory of research. There should be adequate evidence that the primary variable can provide a valid and dependable measure of some clinically pertinent and vital treatment capitalize in the patient population described by the inclusion and exclusion criteria.13-16 Secondary Endpoint

    Typically, secondary endpoints are related to toxicity and undesired effects of the unusual therapy (safety) or to demonstrate additional effects on the disease or condition. The secondary questions necessity to champion and relate to the primary objective and it used to demonstrate additional effects. For the primary objective of “Does the intervention alter mortality rates?” The secondary objective could notice for cause of cardiac death, when death occurred or other cardiac incidents, such as:

  • coronary heart disease mortality
  • incidence of nonfatal myocardial infarction
  • incidence of stroke
  • reduction is risk factor
  • Secondary endpoints likewise may provide evidence that a particular mechanism underlies a demonstrated clinical effect (e.g., a drug for osteoporosis with fractures as the primary endpoint, and improved bone density as a secondary endpoint).17

    Positive results on the secondary endpoints can be interpreted only if there is first a demonstration of a treatment effect on the primary endpoint.

    Exploratory Exploratory endpoints may include clinically vital events that are expected to occur too infrequently to point to a treatment effect or endpoints that for other reasons are thought to be less likely to point to an effect but are included to explore unusual hypotheses.18 Intermediate Clinical Endpoint In a regulatory context, an endpoint measuring a clinical outcome that can be measured earlier than an effect on Irreversible Morbidity or Mortality (IMM) and that is considered reasonably likely to prognosticate the medical product’s effect on IMM or other clinical benefit. The intermediate clinical endpoint may be a basis for replete approval if the effect on the endpoint is considered clinically meaningful. It likewise may be a basis for accelerated approval if the IMM effect is considered critical for employ of the drug or for expedited access for medical devices intended for unmet medical necessity for life threatening or irreversibly debilitating diseases or conditions. Multiple Primary Endpoints (Co-primary Endpoints)

    It may sometimes be desirable to employ more than one primary variable, each of which (or a subset of which) could be adequate to cover the purview of effects of the therapies.19

    Multiple endpoints may be needed when determining that the drug confers a clinical capitalize depends on more than one disease aspect or outcome being affected. Multiple endpoints may likewise be used when:

  • there are several vital aspects of a disease or several ways to assess an vital aspect
  • there is no consensus about which one will best serve the study purposes
  • an effect on any one will be adequate as evidence of effectiveness to champion approval
  • In some cases, multiple aspects of a disease may appropriately be combined into a unique endpoint, but subsequent analysis of the components is generally vital for an adequate understanding of the drug’s effect.20

    Multiple primary endpoints become co-primary endpoints when it is necessary to demonstrate an effect on each of the endpoints to conclude that a drug is effective.

    An sample is treatment of migraine headaches; although stitch is the most prominent feature, migraine headaches are likewise often characterized by the presence of photophobia, phonophobia, and nausea, entire of which are clinically important.

    Composite Endpoints

    There are some disorders for which more than one clinical outcome in a clinical ordeal is important, and entire outcomes are expected to be affected by the treatment.21

    Rather than using each as a divide primary endpoint (creating multiplicity) or selecting just one to be the primary endpoint and designating the others as secondary endpoints, it may be usurp to combine those clinical outcomes into a unique variable or “composite” endpoint,” using a predefined algorithm (e.g., the rating scales used in arthritis, psychiatric disorders, and elsewhere).  This mode is different than multiple primary endpoints and useful to study drugs if component events are infrequent and each component is clinically meaningful.22

    Composite endpoints are often used when the goal of treatment is to forestall or leisurely morbid, clinically vital but uncommon events (e.g., employ of an anti-platelet drug in patients with coronary artery disease to forestall myocardial infarction, stroke and death).

    Surrogate Endpoints

    When direct assessment of the clinical capitalize (or outcomes) to the theme through observing actual clinical efficacy is not practical, indirect criteria may be considered. A surrogate endpoint is a laboratory measure or a physical badge intended to be used as a substitute for a clinically meaningful endpoint and that is reasonably likely to prognosticate clinical capitalize (based on epidemiologic, therapeutic, pathophysiologic or other evidence per 21 CFR 314.510). Such surrogates are less well-established than surrogates in regular use, such as blood pressure for stroke, cholesterol for cardiovascular disease or HIV load for development of AIDS23 and unusual surrogates necessity to be validated. Relationships between clinical and surrogate variables for one product achieve not necessarily apply to a product with a different mode of action for treating the selfsame disease.24,25

    From a US regulatory standpoint, surrogate endpoints and potential surrogate endpoints can be characterized by the following flat of clinical validation:

  • validated surrogate endpoint
  • reasonably likely surrogate endpoint
  • candidate surrogate endpoint26
  • A list of novel drugs approved using surrogate endpoints can be institute on Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure

    Pitfalls of using surrogate endpoints include:

  • uncertainty about clinical benefit
  • potential want of correlation with outcome variable
  • lack of standardization or validation through multiple studies
  • missing long term data
  • possibility of undiscovered risks
  • less information about the episode of rare or delayed adverse events27
  • The flat of evidence necessary to determine whether a surrogate is validated or likely to prognosticate clinical capitalize is made on a case by case basis by FDA.28

    Reasonably Likely Surrogate Endpoint “An endpoint supported by stalwart mechanistic and/or epidemiologic rationale such that an effect on the surrogate endpoint is expected to be correlated with an endpoint intended to assess clinical capitalize in clinical trials, but without adequate clinical data to point to that it is a validated surrogate endpoint. Such endpoints may be used for accelerated approval for drugs and potentially likewise for approval or clearance of medical devices. In the case of accelerated approval for drugs, postmarketing confirmatory trials luxuriate in been required to verify and report the anticipated effect on the irreversible morbidity or mortality or other clinical benefit.”29 Validated Surrogate Endpoint

    “An endpoint supported by a limpid mechanistic rationale and clinical data providing stalwart evidence that an effect on the surrogate endpoint predicts a specific clinical benefit. A validated surrogate endpoint can be used to champion marketing approval of a medical or tobacco product in a defined context without the necessity for additional studies to demonstrate the clinical capitalize directly. Although the term has been used in a conceptually broader way, from a U. regulatory standpoint, a validated surrogate endpoint almost always refers to a biomarker.”30

    Validation information is available on the FDA website.

    Biomarkers

    “A defined characteristic that is measured as an indicator of simple biological processes, pathogenic processes or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiographic or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how an individual feels, functions, or survives. Categories of biomarkers include:”

  • susceptibility/risk biomarker
  • diagnostic biomarker (example: stage a disease)
  • monitoring biomarker (monitoring a response to therapy)
  • prognostic biomarker
  • predictive biomarker (predict a response to a drug)
  • pharmacodynamic/response biomarker
  • safety biomarker31
  • FDA’s Biomarker and Qualification Information

    Biomarkers Used as Outcomes List in development of Approved Products (2007-2015)

    Drug development Too Program and Initiatives

    What contribution is required from the RI strategist?

    Regulatory strategists or intelligence professionals are called upon to inspirit champion the clinical portion of the strategy document or development blueprint by laying out the regulatory acceptable endpoints over the course of development. This means the RI strategist will necessity to:

  • research guidance documents available to understand required endpoints
  • research global past precedent to understand what the regulatory agency has allowed as primary and secondary endpoints for approved drugs in the selfsame class or indication (if no guidance exists)
  • If a company is studying a unusual indication, Key view Leaders (KOL) will be needed to inspirit shape and lead a Scientific Advisory Board (SAB) to inspirit ensure the company is using the most pertinent and measurable endpoints.
  • Endpoints for novel indication will typically further from literature and vetted with the KOLs and eventually the regulatory agency.
  • bring KOLs to regulatory meetings; there are typically several meetings with a regulatory agency (and sometimes advisory committee meetings) to gain agreement on novel endpoints
  • research the literature to understand the touchstone of custody (SOC) in the therapeutic belt across geographical regions
  • understand the changes in the SOC landscape, i.e., forthcoming changes in treatment paradigms as reported by the KOLs (i.e., what the baseline treatment paradigm is and what upcoming treatments or diagnostics methods are being developed over the next few years that should be anticipated and brought into the “Strategy Playbook”)
  • understand the competitive landscape (i.e., what are the endpoints competitors are using, especially if novel or not the selfsame as in the guidance document, if any)
  • plan regulatory interactions with regulatory authorities to propose, dispute and negotiate endpoints, especially if it is a first in class or a unusual indication (and again, this is an iterative process and novel endpoint agreement does not usually occur in a unique meeting)
  • Some things like researching KOLs is obvious—you notice at Pubmed or advocacy groups, but where achieve you start with the endpoints? And what exactly achieve you collect, where achieve you find it and what should the presentation back to the team notice like?

    Evolution of Endpoints by development Phase

    Research should be performed and information organized according to phases of development to ensure a reasonable comparison (Table 2).To be able to recommend what endpoints to employ at what stage, it is vital to understand the evolution of endpoints over the clinical development of a product; from a safety accent in early studies to an efficacy endpoint in later studies. Endpoints disagree by indication and change as disease treatment does.

    Table 2. Endpoints by Phase Phase of Development Typical Endpoints Phase 1
  • Safety assessed after unique and multiple dose administrations:
  • Adverse Events (AE)
  • Labs
  • Physical exam
  • Pharmacokinetics (PK)
  • Pharmacodynamic (PD) endpoints
  • Phase 2A
  • Safety assessed after unique and multiple dose administrations:
  • Adverse Events (AE)
  • Labs
  • Physical exam
  • Pharmacokinetics (PK)
  • Dosing paradigm established
  • Exploratory efficacy endpoints used
  • Phase 2B
  • Safety assessments:
  • Adverse Events (AE)
  • Labs
  • Physical exam
  • Metrics used to establish efficacy further tested and refined, unless efficacy endpoints are dictated by a guidance document
  • Phase 3
  • Efficacy Endpoints refined in previous trials; divided into primary and secondary endpoints
  • Exploratory endpoints
  • Safety assessments:
  • Adverse Events (AE)
  • Labs
  • Physical exam
  • Endpoint Research Where to Start—Free and Fee Tools

    The first cease on any regulatory information gathering mission is to understand what tools are available (free versus fee tools), which ones are available to address a particular question and what each appliance will provide for each piece of the puzzle. Table 3 provides a roadmap for endpoint exploration.

    Where to Start Endpoint Analysis Information Blocking

    Armed with the needed endpoint information and the tools to find it, the next step is to understand how to “block” the information so that it is usable for the analysis. There is a great morass of data to review and categorize, including literature, global guidance documents, past precedent (if available) and the endpoints of trials currently underway as these luxuriate in typically been vetted (or at least discussed) with the agency for the study being conducted. Table 4 provides information to collect for each endpoint.

    Table 4. Endpoint Information Needed to Serve as a Basis for Analysis. Information Needed on Each Endpoint Where to Find it Why Regulatory Precedence and Acceptance

    Previous regulatory filings (Drugs@FDA (or similar))

    Clinicaltrials.gov listing

    Elsevier’s PharmaPendium

  • Understand if the proposed endpoints will be accepted or if you will necessity to toil with regulators to gain their acceptance
  • Current employ of Endpoint in Research

    Country specific guidance documents

    Journal articles

    Drugs@FDA (or similar)

  • Understand what endpoints are being explored as primary, secondary and exploratory endpoints by researchers in the territory as the scientific information could change during the development process
  • What does endpoint really measure?

    Journal articles

    Drugs@FDA (or similar)

  • Understand how to measure the indication.  Sometimes endpoints achieve not measure what you necessity them to and then you necessity to reevaluate the endpoint
  • Some endpoints measure what you want, some what you necessity for regulatory requirements and others what you necessity to understand what endpoints most appropriately measure activity in your indication
  • Positive and negative views on endpoint use

    Journal articles

    Drugs@FDA (or similar)

  • What are the pros and cons to using the proposed endpoints? 
  • Is the scientific information changing and will the endpoints be changing over the timeframe? 
  • Endpoint validated?

    Journal articles

    Drugs@FDA (or similar)

  • Is there a unusual indication that has a unusual endpoint? 
  • Is there a unusual way to measure an endpoint?
  • What are the endpoints that luxuriate in been used to measure the indication in the literature by researchers?
  • What is the acceptance or perception of the endpoints by regulators?
  • What toil will the sponsor necessity to conduct to validate the endpoint?
  • Does validation necessity to be done prior to employ in a study or during the conduct of the study?
  • Will a patient reported outcome be needed or created?
  • Inclusion/Exclusion Population

    Journal articles

    Drugs@FDA (or similar)

    Elsevier’s PharmaPendium

    Country specific guidance documents

  • The indication and patient population is defined by the study’s inclusion and exclusion criteria; this needs to be defined carefully as it will influence the outcome of the development program
  • Only the endpoints that are used most frequently or luxuriate in past regulatory precedence should luxuriate in an in-depth analysis conducted; entire other should be tall flat reporting until the team agrees more analysis is needed. Once the information is acquired to define the output, which can disagree vastly depending on the free or fee tools used, start constructing the output.

    Endpoint Analysis Steps for Information Gathering and Initial Analysis Endpoint Analysis: Free
  • Go to drugs.com and find out what other drugs are in the selfsame class and/or indication; utilize in house expertise as well to inspirit refine the list
  • Add drug names to list in an outstrip spreadsheet
  • Cull endpoint information initially from the label—cannot find the label in drugs.com or Drugs@FDA? vanish to the FDA Online Label Repository where labels are archived
  • Refine list, if in oncology, with the inspirit of NIC databases (Cancer Drug Approval Endpoints, Efficacy Endpoints in Oncology Clinical Trials)
  • Research available global guidance documents in indication (Intelligence Tools, Links and Resources); cull endpoints recommendation into outstrip spreadsheet
  • Pull the Summary Basis of Approvals (Intelligence Tools, Links and Resources) in the countries of choice based on research
  • Pull out the endpoints used for entire past precedent drug into an outstrip worksheet by phase of development
  • From the medical or administrative section (with meeting minutes), cull information on endpoints discussions and issues with it such as want of validation
  • Research current clinical trials being conducted in a clinical ordeal registry for both the indication and class of drugs; add these to the growing spreadsheet (Table 5) (sometimes it helps to achieve this step first prior to entire other activities):
  • Further refine the search by phase of development and download just the trials in phase 1, phase 2, etc., and review those items
  • Look at map of countries and the location of sites being used in the studies
  • Look at synonyms for the disease and review other trials possibly associated with the selfsame disease, but called by a different name
  • Organize by drug name, stage of development and endpoints
  • Research the following literature on PubMed:
  • recent trials in the indication and endpoints used
  • SOC
  • Evolution in changes in the SOC
  • KOLs
  • Download/purchase literature for in-depth review
  • Utilize indication specific (if any) advocacy groups to inspirit refine current endpoints being used by KOLs or to inspirit provide a literature jumping off point; this can be done through an SAB or one on one meetings
  • Analyze the list of endpoints, what are the typical endpoints used, what are the least typical and achieve a profound dive into the endpoints used most often so there is greater clarity on them for team discussion.
  • Put in a format to present the findings to the development team, for group discussion (Table 5) and rate from most frequently used, least used and emerging endpoints
  • This list needs to be reviewed with the Strategy Team and further refined as the Playbook is developed (i.e., this process might necessity to be used a few times and vetted with experts and the regulators).
  • Table 5. Clinicaltrials.gov Output Into Excel.* Title Conditions Interventions Study Designs Outcome Measures Phases Enrollment and Study Type MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Merkel Cell Carcinoma Drug: MLN0128

    Intervention Model: unique Group

    Assignment

    Masking: not a soul (Open Label)

    Primary Purpose: Treatment

    Maximum Tolerated Dose (MTD)

    Overall Response Rate (ORR)

    Overall Survival (OS)

    Progression-Free Survival (PFS)

    Adverse Events (AEs)

    Response Biomarkers, including p4EBP1, PSK6, pCAD and Merkel cell polyomavirus (MCV)

    Large T antigen (LT) and miniature T antigen (ST)

    Phase 1

    Phase 2

    34

    Interventional

    F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma Merkel Cell Carcinoma

    Drug: Arm A: F16IL2 in combination with paclitaxel

    Drug: Arm B: Paclitaxel

    Allocation: Randomized

    Intervention Model: Parallel Assignment

    Masking: not a soul (Open Label)

    Primary Purpose: Treatment

    Efficacy of F16IL2 in combination with paclitaxel vs. paclitaxel monotherapy (RECIST v1.1, irRC)

    Overall survival rate

    Treatment efficacy (ORR, DCR)

    Safety and tolerability of the combination treatment with F16IL2 and paclitaxel

    Phase 2

    90

    Interventional

    A Proof-of-Concept ordeal of GLA-SE in Patients With Merkel Cell Carcinoma Merkel Cell Carcinoma Biological: GLA-SE

    Intervention Model: unique Group Assignment

    Masking: not a soul (Open Label)

    Primary Purpose: Treatment

    Safety and feasibility

    Clinical efficacy and immunogenicity

    Phase 1

    10

    Interventional

    Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation Merkel Cell Carcinoma

    Drug: Ipilimumab

    Drug: Nivolumab

    Allocation: Randomized

    Intervention Model: Parallel Assignment

    Masking: not a soul (Open Label)

    Primary Purpose: Treatment

    Disease-free survival (DFS) at 12 months

    Number of adverse events

    Overall survival rate at 12 months

    DFS rate at 12 months

    Phase 2

    177

    Interventional

    Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma Merkel Cell Carcinoma Drug: Ipilimumab

    Allocation: Non-Randomized

    Intervention Model: unique Group Assignment

    Masking: not a soul (Open Label)

    Primary Purpose: Treatment

    Overall survival at 12 months with ipilimumab treatment

    Determine the best overall response rate, median survival, disease-specific survival and progression free survival

    Determine median survival, disease-specific survival and progression nfree survival

    Phase 2

    0

    Interventional

    QUILT-3.009: Study of aNK Infusions in Combination With ALT-803 in Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

    Stage IIIB Merkel Cell Carcinoma

    Stage IV Merkel Cell Carcinoma

    Biological: aNK (NK-92)

    Intervention Model: unique Group Assignment

    Masking: not a soul (Open Label)

    Primary Purpose: Treatment

    Progression Free Survival

    Overall Response Rate

    Time to disease progression

    Overall survival

    Safety and tolerability of aNK in combination with ALT-803

    Quality of life assessment

    Phase 2

    24

    Interventional

    *Need to Specify Fields to Download. Endpoint Analysis: Fee Figure 1. Organized Endpoint Output for BizInt Smart Charts (Combined Output from a Variety of Clinical Registries). Brown-Tuttle-Fig-1.jpg
  • Go to PharmaPendium, input the indication and class as search terms, cull results for a list of drugs approved for indication and class and endpoints in medical reviews; utilize in house expertise to inspirit refine the list; attach results into an outstrip spreadsheet
  • Pull out the endpoints used for entire past precedent drug into an outstrip worksheet, by phase of development
  • From the medical or administrative section (with meeting minutes) cull information on endpoints discussions and issues with it such as want of validation
  • Research available global guidance documents in indication; cull endpoints recommendation into outstrip spreadsheet using Tarius or Clarivate Analytics Cortellis
  • Ask Nerac to conduct a literature search for you looking at SOC, KOLs, emerging treatments and endpoints used for indication
  • Or quiz a Librarian to conduct the literature search for you
  • Ask librarian or literature search service to download/obtain literature
  • Review and attach results into an outstrip spreadsheet
  • Analyze the list of endpoints, attach in a format to present your findings to the development team, for group discussion
  • Regulatory Pathway Dictated by kind of Endpoint Used

    Something to withhold in mind when finalizing and incorporating endpoints into a strategy, the kind of endpoint selected can dictate the regulatory approval pathway that needs to be followed. Review Table 6 to ensure alignment with regulatory expectations.

    Table 6. Endpoints and Predicted Regulatory Pathway. Type of Endpoint What it Does Regulatory Pathway Clinical Benefit How a patient feels, functions or survives Regular* Validated Surrogate Recognized as validated through multiple definitive studies Regular* Surrogate Reasonably likely to prognosticate clinical benefit Accelerated Approval *Could be accelerated or priority review based on the unmet medical necessity or seriousness of indication.32

    Communicating the Data Back to the Stakeholders

    Once the needed information is available to define the output, which can disagree vastly depending on the free or fee tools used and the specific indication, open constructing the output and understand what is needed for the output. One of the biggest issues in analyzing data, since it is so onerous, is the presentation back to the team and deciding the most efficient shape is should take. On the backend, there is a lot of data that needs to be cleaned, merged or manually manipulated and since it is disparate, it can be very difficult to summarize, especially endpoints. Most teams want a high-level analysis that is interactive so as to respond immediate questions and an outstrip spreadsheet does not luxuriate in visual appeal; this is where a “fee” product really is helpful in presenting a brightly colorful and interactive output.

    Case Study—Merkle Cell Carcinoma

    The following case study discusses the indication of the rare disease Merkle Cell Carcinoma (MCC) and demonstrates how to attach the above information into practice. Note: only one drug has been approved for this indication [BAVENCIO [AVELUMAB]] (approved 23 March 2017).

    New Regulatory Intelligence Tool

    BizInt Smart Charts Drug development Suite is purpose-built software designed to facilitate creating, customizing and distributing tabular reports from selected clinical trial, drug pipeline and biomedical journal databases. Reflecting more than 20 years of feedback from users in pharmaceutical and biotech companies, it replaces the necessity to write complicated macros and manually manipulate data in outstrip and Word. Data from supported databases (see below) is imported and formatted into tables, and the fields/columns included in your report can be changed at any time. BizInt Smart Charts automatically identifies the selfsame ordeal across different databases and the selfsame drug across pipeline databases and has tools to merge different database records on the selfsame ordeal into a unique integrated row in your report.

    A second tool, VantagePoint - Smart Charts Edition, has the ability to further refine the data, extract terms and create visualizations for PowerPoint presentations. Table 7 provides an overview of the databases that BizInt Smart Charts can pull from to inspirit compile endpoint information.

    Table 7. BizInt Smart Charts Drug development Suite—Supported Databases. Supported Clinical ordeal Databases Supported Pipeline Databases Supported Biomedical Journal Databases

    Registry:Clinical Trials.govEU Clinical Trials RegistryWHO ICTRP

    Commercial:Citeline TrialtroveAdis Clinical Trials InsightCortellis Clinical Trials

    Citeline PharmaprojectsClarivate Analytics CortellisIMS R&D FocusAdis R&D InsightClarivate Integrity

    Medline/PubMedBIOSISEMBASE

    BizInt Smart Charts was used to collect endpoint information from a variety of Clinical ordeal Registries for MCC and this was compared with the collection and analysis times done without the appliance (Table 8).  Overwhelmingly, the appliance shaved more than 100 hours off of the stint at hand (two weeks of work.)

    Table 8: Mining Clinical ordeal Registry Data for Endpoints—Time Comparison of the Free and For Fee Tools Steps Taken Tools Used Free Time Fee Time Search databases for “Merkle Cell Carcinoma” and download results to outstrip spreadsheet

    WHO—ICTRP Search Portal

    Drugs@FDA Database

    10 min 10 min

    Open up the spreadsheets and combine the trials

  • Google Worksheets
  • MS Excel
  • 5 min

    (Figure 1)

    2 min

    Go through and remove the duplicates and/or merge the information for the selfsame trials listed in multiple databases

  • Google Worksheets
  • MS Excel
  • 100+ min 5 min
  • Delete or sprint around fields so that pertinent information is displayed in first few rows
  • Hide rows so that they are quiet available but not distracting your analysis
  • Google Worksheets
  • MS Excel
  • 45+ min 20
  • Analyze what is pertinent to your program to be able to fabricate recommendations to the team
  • Brain power and experience

    200+ min

    Brain power and experience

    200+ min
  • Put together the information in a way easily incorporated into the Strategy Playbook
  • Google Worksheets
  • MS Excel
  • 60+ min
  • PowerPoint
  • BizInt Smart Charts
  • 30 min
  • Put together information in a PowerPoint slide for presentation to the team
  • Google Worksheets
  • MS Excel
  • PowerPoint
  • 60+ min
  • PowerPoint
  • BizInt Smart Charts
  • 30 min Total Time 480+ min ~297 min Case Study Conclusion

    Overall, while some of the steps are the same, the fee tools achieve provide quicker information output which can lead to quicker analysis and feedback to the team. BizInt Smart Charts and VantagePoint significantly slice down on the time it took to research endpoints making the time to respond to the team quicker and the output visually pleasing (which would luxuriate in taken a lot longer to achieve manually) and interactive, which really worked well for the team and because questions were able to be answered on the spot versus looking through a pile of notes. 

    Summary

    As a parting note, remember the “Strategy Playbook” must be reviewed on an annual basis as scientific data and the requirements for a program change over time, so keeping complete notes and output are vital to inspirit evaluate data as it evolves.

    References
  • Multiple Endpoints in Clinical Trials. Guidance for Industry. January 2017. FDA website https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm536750.pdf. Accessed 21 September 2018.
  • Federal Food, Drug, and Cosmetic Act (FD&C). FDA website. https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/FederalFoodDrugandCosmeticActFDCAct/default.htm. Accessed 21 September 2018.
  • Kefauver-Harris Amendments Revolutionized Drug Development. FDA website. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm322856.htm. Accessed 21 September 2018.
  • Carpenter D. Reputation and Power. Organizational Image and Pharmaceutical Regulation at the FDA. Princeton University Press. https://press.princeton.edu/titles/9205.html. Accessed 21 September 2018.
  • Guidance for Industry. Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. May 1998. FDA website. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072008.pdf. Accessed 21 September 2018.
  • BEST (Biomarkers, EndpointS, and other Tools) Resource. May 2018. FDA-NIH Biomarker Working Group. https://www.ncbi.nlm.nih.gov/books/NBK326791/pdf/Bookshelf_NBK326791.pdf. Accessed 21 September 2018.
  • Defining Clinical capitalize in Clinical Trials: FDA Perspective. Presentation by Jessica J. Lee, MD, MMSc. https://celiac.org/wp/wp-content/uploads/2015/04/great3-07.pdf. Accessed 21 September 2018.
  • Guidance for Industry. Clinical ordeal Endpoints for the Approval of Cancer Drugs and Biologics. May 2007. FDA website. https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf. Accessed 21 September 2018.
  • FDA Facts: Biomarkers and Surrogate Endpoints. FDA website. https://www.fda.gov/aboutfda/innovation/ucm512503.htm. Accessed 21 September 2018.
  • Op cit 6.
  • National Cancer Institute (NCI) Dictionary of Cancer Terms. NCI website. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/endpoint. Accessed 22 September 2018.
  • Measuring How Patients Feel and Function. Presentation by Michelle Campbell, PhD. Roadmap to Engaging CDER Public Workshop. May 2017. FDA website. https://www.fda.gov/downloads/Drugs/NewsEvents/UCM558288.pdf. Accessed 22 September 2018.
  • Op cit 11.
  • HIV/AIDS Glossary. Clinical Endpoint. https://aidsinfo.nih.gov/understanding-hiv-aids/glossary/840/clinical-endpoint . Accessed 22 September 2018.
  • Op cit 1.
  • Guidance for Industry. E9 Statistical Principles for Clinical Trials. September 1998. FDA website.  https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073137.pdf . Accessed 22 September 2018.
  • Op cit 1.
  • Op cit 1.
  • Op cit 16.
  • Op cit 1.
  • Op cit 1.
  • Op cit 16.
  • Op cit 9.
  • Op cit 16.
  • Clinical ordeal Endpoints. Presentation by Eugene J. Sullivan, MD FCCP. FDA website. https://www.fda.gov/downloads/Training/ClinicalInvestigatorTrainingCourse/UCM337268.pdf. Accessed 23 September 2018.
  • Op cit 6.
  • FDA Regulatory Considerations for NASH Clinical ordeal Endpoints. Presentation by Stephanie O. Omokaro, PhD. Global NASH Congress. https://www.slideshare.net/JaneWilliams25/fda-regulatory-considerations-for-nash-clinical-trial-endpoints
  • Sanyal AJ, Friedman SL, McCullough AJ  and Dimick-Santos L. “Challenges and Opportunities in Drug and Biomarker development for Nonalcoholic Steatohepatitis.” Findings and recommendations from an American Association for the Study of Liver Diseases and FDA  Joint Workshop. https://www.ncbi.nlm.nih.gov/pubmed/25557690. Accessed 23September 2018.
  • Op cit 6.
  • Op cit 6.
  • Op cit 6.
  • Op cit 27.
  • About the Author

    Meredith Brown-Tuttle, RAC, FRAPS, is the principal consultant for Regulatorium, a company specializing in regulatory intelligence, writing and strategy. She is the author of IND Submissions: A Primer, published by Barnett, Regulatory Intelligence 101, published by RAPS, numerous articles and serves as chair of the RAPS Editorial Advisory Committee. She can be reached at theregulatorium@gmail.com.

    Cite as: Brown-Tuttle M. “The Regulatory Strategist Toolbox: Clinical Endpoint Analysis Tools.” Regulatory Focus. September 2018. Regulatory Affairs Professionals Society.



    Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [8 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [101 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [20 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [43 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [48 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institute [4 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    CyberArk [1 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [11 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [22 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [128 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [14 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [752 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1533 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [65 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [68 Certification Exam(s) ]
    Microsoft [375 Certification Exam(s) ]
    Mile2 [3 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [3 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [39 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [282 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [12 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real Estate [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [135 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]





    References :


    Issu : https://issuu.com/trutrainers/docs/c2010-659
    Dropmark : http://killexams.dropmark.com/367904/11723375
    Wordpress : http://wp.me/p7SJ6L-1jK
    Dropmark-Text : http://killexams.dropmark.com/367904/12294714
    Blogspot : http://killexamsbraindump.blogspot.com/2017/11/people-used-these-ibm-dumps-to-get-100_23.html
    RSS Feed : http://feeds.feedburner.com/JustMemorizeTheseC2010-659QuestionsBeforeYouGoForTest
    Box.net : https://app.box.com/s/xecttre1u46svjbe0yfbek84vjk13wl1
    publitas.com : https://view.publitas.com/trutrainers-inc/where-can-i-get-help-to-pass-c2010-659-exam killexams.com helps millions of candidates pass the exams and find their certifications. They luxuriate in thousands of successful reviews. Their dumps are reliable, affordable, updated and of really best quality to overcome the difficulties of any IT certifications. killexams.com exam dumps are latest updated in highly outclass manner on regular basis and material is released periodically. Latest killexams.com dumps are available in testing centers with whom they are maintaining their relationship to find latest material. The killexams.com exam questions for C2010-659 Fundamentals of Applying SmartCloud Control Desk V1 exam is mainly based on two accessible formats, PDF and practice questions. PDF file carries entire the exam questions, answers which makes your preparation easier. While the practice questions are the complimentary feature in the exam product. Which helps to self-assess your progress. The evaluation appliance likewise highlights your feeble areas, where you necessity to attach more efforts so that you can ameliorate entire your concerns. Killexams.com recommend you to must try its free demo, you will notice the intuitive UI and likewise you will find it very simple to customize the preparation mode. But fabricate positive that, the actual C2010-659 product has more features than the ordeal version. If, you are contented with its demo then you can purchase the actual C2010-659 exam product. Avail 3 months Free updates upon purchase of C2010-659 Fundamentals of Applying SmartCloud Control Desk V1 Exam questions. killexams.com offers you three months free update upon acquisition of C2010-659 Fundamentals of Applying SmartCloud Control Desk V1 exam questions. Their expert team is always available at back conclude who updates the content as and when required. Killexams.com Huge Discount Coupons and Promo Codes are as under; WC2017 : 60% Discount Coupon for entire exams on website PROF17 : 10% Discount Coupon for Orders greater than $69 DEAL17 : 15% Discount Coupon for Orders greater than $99 DECSPECIAL : 10% Special Discount Coupon for entire Orders Source / Reference: https://issuu.com/trutrainers/docs/c2010-659 http://killexams.dropmark.com/367904/11723375 http://wp.me/p7SJ6L-1jK http://killexams.dropmark.com/367904/12294714 http://killexamsbraindump.blogspot.com/2017/11/people-used-these-ibm-dumps-to-get-100_23.html http://feeds.feedburner.com/JustMemorizeTheseC2010-659QuestionsBeforeYouGoForTest https://app.box.com/s/xecttre1u46svjbe0yfbek84vjk13wl1
    zoho.com : https://docs.zoho.com/file/5xmi625ce05221f214b3a9ce4cc62e02dd8c9






    Back to Main Page





    Killexams C2010-659 exams | Killexams C2010-659 cert | Pass4Sure C2010-659 questions | Pass4sure C2010-659 | pass-guaratee C2010-659 | best C2010-659 test preparation | best C2010-659 training guides | C2010-659 examcollection | killexams | killexams C2010-659 review | killexams C2010-659 legit | kill C2010-659 example | kill C2010-659 example journalism | kill exams C2010-659 reviews | kill exam ripoff report | review C2010-659 | review C2010-659 quizlet | review C2010-659 login | review C2010-659 archives | review C2010-659 sheet | legitimate C2010-659 | legit C2010-659 | legitimacy C2010-659 | legitimation C2010-659 | legit C2010-659 check | legitimate C2010-659 program | legitimize C2010-659 | legitimate C2010-659 business | legitimate C2010-659 definition | legit C2010-659 site | legit online banking | legit C2010-659 website | legitimacy C2010-659 definition | >pass 4 sure | pass for sure | p4s | pass4sure certification | pass4sure exam | IT certification | IT Exam | C2010-659 material provider | pass4sure login | pass4sure C2010-659 exams | pass4sure C2010-659 reviews | pass4sure aws | pass4sure C2010-659 security | pass4sure coupon | pass4sure C2010-659 dumps | pass4sure cissp | pass4sure C2010-659 braindumps | pass4sure C2010-659 test | pass4sure C2010-659 torrent | pass4sure C2010-659 download | pass4surekey | pass4sure cap | pass4sure free | examsoft | examsoft login | exams | exams free | examsolutions | exams4pilots | examsoft download | exams questions | examslocal | exams practice |

    www.pass4surez.com | www.killcerts.com | www.search4exams.com | http://tractaricurteadearges.ro/